KPV10mg
KPV Canada — 10 mg, 30 mg Lyophilized Vials
Tripeptide Research Compound
KPV is a tripeptide studied in laboratory settings for its role in inflammatory signaling pathways and immune-related cellular responses. Research often explores its interaction with cytokine regulation and tissue response mechanisms in controlled experimental models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
KPV is a synthetic tripeptide composed of lysine–proline–valine and represents a fragment derived from the alpha-melanocyte–stimulating hormone (α-MSH) sequence. It is developed for controlled laboratory research involving peptide-mediated signaling systems.
In scientific literature, KPV is studied in experimental models examining inflammatory signaling pathways, cytokine-associated regulatory frameworks, and epithelial interaction systems under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
KPV is the C-terminal tripeptide fragment of α-MSH and has been evaluated in research focused on immune-related signaling pathways and epithelial system interaction models. Experimental studies examine its interaction within inflammatory regulatory frameworks and peptide-mediated signaling systems in controlled laboratory environments.
Research publications have explored its pathway-level regulatory characteristics and signaling behavior under structured experimental conditions.
The parent peptide α-MSH was originally studied for its role in melanocortin signaling systems. Subsequent biochemical investigations identified smaller active fragments, including KPV, for further experimental evaluation.
Research expanded into models exploring peptide fragment interaction within inflammatory and epithelial signaling systems under laboratory conditions.
Laboratory investigations into KPV have focused on inflammatory signaling pathway models and epithelial system regulatory frameworks. Research environments evaluate peptide interaction within cytokine-associated signaling systems and cellular response mechanisms under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on inflammatory. This heading marks where KPV is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on cytokine. This heading marks where KPV is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on epithelial or interaction. This heading marks where KPV is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Xiao 2017, Dalmasso 2008. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 2008 and 2017 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for KPV, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
KPV is also referred to as KPV.
Described as an anti-inflammatory peptide for gut and skin conditions.
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone, and the published research examines anti-inflammatory signalling in cell-culture and animal models of colitis and dermal inflammation. No controlled human efficacy trial has been published, and it is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for KPV is per lot, not per product. Across the strengths currently stocked: 30mg lot KPV-CA-26A-01 returned 99.801% purity, 37.52 mg measured, 125.1% of the labelled 30 mg; 10mg lot KPV-CA-26I-10 returned 99.103% purity, 11.56 mg measured, 115.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is KPV; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for KPV, across the strengths stocked they run from 115.6% to 125.1% of label. Both numbers are published for every lot, whichever way they fall.
Each strength of KPV carries its own lot code and its own certificate — KPV-CA-26A-01, KPV-CA-26I-10 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy KPV in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
KPV is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 3 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 30mg of lyophilized KPV. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.
PubMedDrug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
PubMedPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
